Results 251 to 260 of about 1,974,684 (305)
Some of the next articles are maybe not open access.
Current Opinion in Pulmonary Medicine, 2010
The use of immunomodulators in asthma has been well established with omalizumab. Evidence is accumulating for other biologic agents. The following article presents an overview of current biologic therapies employed and under investigation in the treatment of asthma.Anti-immunoglobulin E and anti-interleukin-5 are best supported by current evidence ...
David, Gruenberg, William, Busse
openaire +2 more sources
The use of immunomodulators in asthma has been well established with omalizumab. Evidence is accumulating for other biologic agents. The following article presents an overview of current biologic therapies employed and under investigation in the treatment of asthma.Anti-immunoglobulin E and anti-interleukin-5 are best supported by current evidence ...
David, Gruenberg, William, Busse
openaire +2 more sources
Biological therapies in otology
HNO, 2017Hearing loss is present in millions of people worldwide. Current treatment for patients with severe to profound hearing loss consists of cochlear implantation. Providing the cochlear nerve is intact, patients generally benefit greatly from this intervention, frequently achieving significant improvements in speech comprehension. There are, however, some
A, Roemer +4 more
openaire +2 more sources
Seminars in Respiratory and Critical Care Medicine, 2018
AbstractAlthough airway inflammation is an intrinsic and key feature of asthma, this response varies in its intensity and translation to clinical characteristics and responsiveness to treatment. The observations that clinical heterogeneity is an important aspect of asthma and a feature that likely dictates and determines responses to treatment in ...
Ravi K, Viswanathan, William W, Busse
openaire +2 more sources
AbstractAlthough airway inflammation is an intrinsic and key feature of asthma, this response varies in its intensity and translation to clinical characteristics and responsiveness to treatment. The observations that clinical heterogeneity is an important aspect of asthma and a feature that likely dictates and determines responses to treatment in ...
Ravi K, Viswanathan, William W, Busse
openaire +2 more sources
Biological Therapies in Osteoarthritis
Current Pharmaceutical Design, 2015Given the paucity of effective therapies and the increasing prevalence of osteoarthritis (OA) with ageing and overweight populations, new therapies for this painful, life-impairing condition are desperately needed, for both symptom relief and structural modification.
Claire Y J, Wenham +2 more
openaire +2 more sources
Economics of biological therapies
BMJ, 2009Demand for biological drugs is putting pressure on health budgets.
Christopher J, Kelly, Fraz A, Mir
openaire +2 more sources
Biological therapy for psoriasis
British Journal of Hospital Medicine, 2006Psoriasis is a common, chronic immune-mediated skin disorder. Recent advances in the understanding of the immunopathogenesis of psoriasis have led to the development of biological agents designed to target the molecular mechanisms of the condition. These provide new and effective treatments for patients with moderate to severe psoriasis.
Suzanne E, Clements +2 more
openaire +2 more sources
Biologically Optimized Radiation Therapy
Acta Oncologica, 2001Advanced treatment optimization is possible using quantitative radiobiological dose response models. Although all present models are necessarily linked to a certain degree of uncertainty, this will only have a small influence on the relative shape of the resultant optimal dose distribution.
A, Brahme, J, Nilsson, D, Belkic
openaire +2 more sources
Pharmacoeconomics of Biologic Therapy
Immunology and Allergy Clinics of North America, 2017Novel biologic agents have allowed clinicians to achieve improved patient outcomes. Appropriate pharmacoceconomic analyses demand evaluation of all relevant costs, including the treatments, the disease and comorbidities, and costs of alternative treatments, including their short- and long-term side effects.
Don A, Bukstein, Allan T, Luskin
openaire +2 more sources
Inflammatory Bowel Diseases, 2007
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources